Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Return on Capital Employed (ROCE) | 18.5% | 19.5% | 18.1% | 25.0% | 29.6% | 35.6% | 40.4% | 52.5% | 53.6% | 60.1% | 86.6% | 76.3% | 72.9% | 68.4% | 69.6% | 61.1% | 55.8% | 56.9% | 61.5% | 52.0% |
Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.
As of today, Microsoft Corp's last 12-month Return on Capital Employed (ROCE) is 46.8%, based on the financial report for Dec 31, 2024 (Q4 2024). The average annual Return on Capital Employed (ROCE) for Novo Nordisk A/S have been 52.5% over the past three years, and 57.5% over the past five years.
As of today, Novo Nordisk A/S's Return on Capital Employed (ROCE) is 46.8%, which is higher than industry median of (51.5%). It indicates that Novo Nordisk A/S's Return on Capital Employed (ROCE) is Good.